No connection

Search Results

BFRI vs XWEL

BFRI
Biofrontera Inc.
BEARISH
Price
$0.86
Market Cap
$10.0M
Sector
Healthcare
AI Confidence
92%
XWEL
XWELL, Inc.
BEARISH
Price
$1.14
Market Cap
$9.0M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
BFRI
--
XWEL
--
Forward P/E
BFRI
-3.72
XWEL
-0.43
P/B Ratio
BFRI
-3.85
XWEL
-1.04
P/S Ratio
BFRI
0.27
XWEL
0.31
EV/EBITDA
BFRI
-0.65
XWEL
-3.37

Profitability

Gross Margin
BFRI
64.41%
XWEL
25.7%
Operating Margin
BFRI
-89.84%
XWEL
-45.07%
Profit Margin
BFRI
-47.28%
XWEL
-58.17%
ROE
BFRI
-1191.73%
XWEL
--
ROA
BFRI
-64.91%
XWEL
-31.98%

Growth

Revenue Growth
BFRI
-22.5%
XWEL
-4.2%
Earnings Growth
BFRI
--
XWEL
--

Financial Health

Debt/Equity
BFRI
--
XWEL
--
Current Ratio
BFRI
1.15
XWEL
0.46
Quick Ratio
BFRI
0.51
XWEL
0.33

Dividends

Dividend Yield
BFRI
--
XWEL
--
Payout Ratio
BFRI
0.0%
XWEL
0.0%

AI Verdict

BFRI BEARISH

BFRI exhibits severe financial distress, reflected in a Piotroski F-Score of 1/9 (indicating weak financial health) and a lack of Altman Z-Score data, which raises red flags for potential bankruptcy risk. The company reports massive losses with a -47.28% profit margin, negative ROE (-1191.73%), and declining revenue (YoY -22.50%). Despite a strong gross margin (64.41%), operational inefficiencies and negative cash flows undermine sustainability. The stock trades at a deep discount (Price/Sales: 0.27), but this is not a value signal—rather, it reflects deteriorating fundamentals and investor skepticism. Analysts' 'strong_buy' recommendation appears disconnected from the underlying data.

Strengths
High gross margin (64.41%) suggests potential pricing power or low production costs
Recent 1-month price increase (+3.1%) indicates short-term momentum
Analyst consensus is 'strong_buy' despite poor fundamentals, suggesting potential catalyst expectations
Risks
Piotroski F-Score of 1/9 indicates extreme financial weakness and poor operational performance
Negative ROE (-1191.73%) and ROA (-64.91%) signal severe capital inefficiency and loss of shareholder value
Consistent earnings misses in the last 4 quarters (0/4 beats, average surprise -88.35%) reflect deteriorating execution
XWEL BEARISH

XWEL exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -1.04, indicating negative shareholder equity. The company is facing a liquidity crisis with a Current Ratio of 0.46 and a Quick Ratio of 0.33, suggesting it cannot meet its short-term obligations. While there has been a speculative 1-year price recovery and recent EPS 'beats,' these are relative to deeply negative expectations and do not offset the fundamental insolvency risks. The combination of declining revenue (-4.20% YoY) and negative margins makes the current valuation unsustainable.

Strengths
Low Price-to-Sales ratio (0.31) suggests the market has already priced in significant failure
Recent quarterly EPS surprises have been positive (beating negative estimates)
Short-term 1-year price performance shows speculative interest (+48%)
Risks
Extreme bankruptcy risk indicated by Piotroski F-Score of 1/9
Negative equity (P/B -1.04) indicates liabilities exceed assets
Severe liquidity shortage with a Current Ratio well below 1.0 (0.46)

Compare Another Pair

BFRI vs XWEL: Head-to-Head Comparison

This page compares Biofrontera Inc. (BFRI) and XWELL, Inc. (XWEL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile